Holen Sie sich die Stockscreener-App
2.94
0.34%
0.010
Handel nachbörslich:
2.93
-0.010
-0.34%
Schlusskurs vom Vortag:
$2.93
Offen:
$2.96
24-Stunden-Volumen:
23,454
Relative Volume:
0.01
Marktkapitalisierung:
$4.46M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.91M
KGV:
-0.4395
EPS:
-6.69
Netto-Cashflow:
$-6.14M
1W Leistung:
+2.08%
1M Leistung:
-22.63%
6M Leistung:
-39.51%
1J Leistung:
-39.82%
1-Tages-Spanne:
$2.84
$2.98
1-Wochen-Bereich:
$2.84
$3.18
52-Wochen-Spanne:
$2.73
$23.80
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Firmenname
Galmed Pharmaceuticals Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GLMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| GLMD | 2.94 | 4.46M | 0 | -6.91M | -6.14M | -6.69 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-05-22 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | Eingeleitet | Craig Hallum | Buy |
| 2020-01-30 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-12-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-08-02 | Bestätigt | Maxim Group | Buy |
| 2018-07-13 | Eingeleitet | Stifel | Buy |
| 2018-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-06-12 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2018-02-14 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-15 | Eingeleitet | ROTH Capital | Buy |
| 2017-08-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Bestätigt | Maxim Group | Buy |
| 2016-08-01 | Bestätigt | Maxim Group | Buy |
| 2016-07-06 | Fortgesetzt | ROTH Capital | Buy |
| 2016-03-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-05-06 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Galmed Pharmaceuticals Ltd Aktie (GLMD) Neueste Nachrichten
Galmed Pharmaceuticals: Q3 Earnings Snapshot - New Haven Register
Galmed Pharmaceuticals Embraces Market with New Sales Agreement - TipRanks
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Galmed Phar stock hits 52-week low at $2.73 amid challenges - Investing.com Australia
Galmed Pharmaceuticals Amends Equity Purchase Agreement - TipRanks
Acyl CoA Desaturase Market Current Status and Future Prospects - IndiaPolitics.com
galmed pharmaceuticals ltd. Earnings dates - RTTNews
Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Passes Above 50-Day Moving Average of $4.52 - Defense World
United States shares lower at close of trade; Dow Jones Industrial Average down 0.25% - MSN
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.25% - MSN
(GLMD) Long Term Investment Analysis - Stock Traders Daily
Galmed reports positive results for Aramchol in NASH study By Investing.com - Investing.com Australia
Galmed reports positive results for Aramchol in NASH study - Investing.com India
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology - PR Newswire
Post-Trade Analysis: Galmed Pharmaceuticals Ltd (GLMD) Slides -13.90, Closing at 8.05 - The Dwinnex
Take off with Galmed Pharmaceuticals Ltd (GLMD): Get ready for trading - SETE News
Understanding GLMD stock ratios for better investment decisions - US Post News
GLMD’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Optimistic Market Report Drives Galmed Pharmaceuticals (GLMD) Stock Upward - Stocks Telegraph
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs - GlobeNewswire
Galmed Pharmaceuticals Calls for Capital Increase Vote - TipRanks
Galmed expands drug development to cancer and heart diseases - Investing.com
Galmed surges on plans to expand into cancer and heart disease drug development - XM
Galmed Pharmaceuticals Stock Is Soaring Thursday: Here's Why - Benzinga
Market Insights: Galmed Pharmaceuticals Ltd (GLMD)’s Notable Drop of -54.30, Closing at 6.90 - The Dwinnex
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases - PR Newswire
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases | GLMD Stock News - StockTitan
B. Riley FBR Downgrades Galmed Pharmaceuticals Ltd (GLMD) to a Neutral from a Buy - Knox Daily
Galmed Pharmaceuticals Down 53%, But Still Well Above Monday Closing Price - MarketWatch
US Stocks Mixed; General Mills Posts Upbeat Earnings - Benzinga
A new trading data show Galmed Pharmaceuticals Ltd (GLMD) is showing positive returns. - SETE News
Galmed Pharmaceuticals Soars Nearly 500% Amid Nasdaq Compliance and Short Squeeze - TipRanks
Those who invested in Neuren Pharmaceuticals (ASX:NEU) three years ago are up 576% - Yahoo Finance
Galmed Pharmaceuticals Surges 400%: What's Behind the Explosion? - MarketBeat
Gold Edges Lower; US Homebuilder Sentiment Rises For September - Benzinga
Galmed Pharmaceuticals Surges After Regaining Nasdaq Compliance - MarketWatch
Galmed Pharmaceuticals Ltd’s Banking’s 100-Day Moving Average at 4.01: Will the Stock Break Through? - The InvestChronicle
Stock Market news: Galmed Pharmaceuticals soars 283%, Intel up 3.49%, while Tupperware plunges 57% - Business Upturn
Express Scripts sues FTC and demands drug pricing report retraction - Yahoo! Voices
With its newest mac and cheese, Stouffer's expands beyond the freezer aisle to supermarket shelves - Yahoo! Voices
Merit Medical touts positive six-month data from WAVE trial - Yahoo! Voices
Lunds & Byerlys digitizes refrigeration compliance management - Yahoo! Voices
Crude Oil Gains Over 1%; US Business Inventories Increase In July - Benzinga
Philip Morris to sell Vectura for $198 million after health shift criticism - Yahoo Finance
Why Shares of Gannett Are Soaring Today - Yahoo Finance
Galmed Pharma stock hits 52-week high at $10.51 - Investing.com
FanDuel Parent Buys Italian Gaming Operator Snai for $2.56 Billion - Yahoo! Voices
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution - Yahoo Finance
Intel's Amazon chip deal lifts investor confidence in money-losing foundry unit - Yahoo! Voices
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Yahoo Finance
Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results - Yahoo Finance
Finanzdaten der Galmed Pharmaceuticals Ltd-Aktie (GLMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):